October 5, 2025

Efficacy and Predictors of Low-Dose Abrocitinib in Chinese Adults with Moderate-to-Severe Atopic Dermatitis: A Prospective Study.

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Prospective study shows 60% EASI-75 response in adults with atopic dermatitis, indicating effectiveness and safety.

At Week 12, 60.0% of participants achieved EASI-75, indicating significant effectiveness of abrocitinib in treating atopic dermatitis.
EASI improvements of -90.8% and a notable reduction in pruritus were recorded, highlighting the therapeutic benefit of low-dose abrocitinib.
The study employed a prospective design, analyzing data from a total of 40 adult patients receiving abrocitinib over 24 weeks.
Findings suggest that baseline IgE levels may predict treatment response, supporting personalized approaches to atopic dermatitis management.

Zhang et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark